Moreover, because β-lap alone induces tumor programmed necrotic cell death that could induce many cytokines or other side effects in vivo, our recent report revealed that low-dose β-lap combined with a PARP inhibitor switched the pathway to apoptosis (11), which implies that combination therapy between β-lap and other clinical drugs would be worth exploring. Here, PARP1 is linked to neoplasm.